Expert Insights

Part 1: Identifying Patients With Advanced PV

Read transcript Close transcript

Dr Shammo: Polycythemia vera is a hematological malignancy that may become advanced in a subset of patients despite treatment with hydroxyurea and phlebotomy, resulting in ineffective disease control.

Narrator: Clinical characteristics of advanced PV may include hematocrit greater than or equal to 45% plus one additional risk factor despite treatment with hydroxyurea and phlebotomy. Specifically, clinical characteristics of advanced PV may include hematocrit greater than or equal to 45% plus elevated white blood cell count greater than 11x109 per liter or burdensome disease-related symptoms such as fatigue, early satiety, inactivity, concentration problems, and itching.

Dr Shammo: Well, anytime you have a patient who has PV and has a hematocrit greater than 45%, you can correctly assume that the risk of thrombosis is definitely elevated. And the same could be said, although somewhat hampered by the retrospective nature of that finding, but I think it would be reasonable to also say that leukocytosis can also represent another factor for the increased risk of thrombosis.

I think the symptom burden of patients who have PV have been largely underrepresented and underappreciated.

Narrator: Actively monitor for hematocrit plus in your patients with polycythemia vera.

Image of Jamile M Shammo, MD, FASCP, FACP
Jamile M Shammo, MD, FASCP, FACP Associate Professor Rush University Medical Center | Chicago, IL

Meet the Experts

Image of Jamile M Shammo, MD, FASCP, FACP
Jamile M Shammo, MD, FASCP, FACP Associate Professor Rush University Medical Center Chicago, IL SEE MORE FROM THIS EXPERT
Image of Raajit K Rampal, MD, PhD
Raajit K Rampal, MD, PhD Hematologic Oncologist Memorial Sloan Kettering Cancer Center New York, NY SEE MORE FROM THIS EXPERT
Image of Kim-Hien Dao, DO, PhD
Kim-Hien Dao, DO, PhD Assistant Professor of Medicine Knight Cancer Institute, Center for Hematologic Malignancies Oregon Health & Science University Portland, OR SEE MORE FROM THIS EXPERT
Image of Jerry Spivak, MD
Jerry Spivak, MD Professor of Medicine and Oncology Director Center for the Chronic Myeloproliferative Disorders Johns Hopkins University School of Medicine Baltimore, MD SEE MORE FROM THIS EXPERT
Image of Rami S Komrokji, MD
Rami S Komrokji, MD Clinical Director of the Malignant Hematology Department Moffitt Cancer Center
Tampa, FL
SEE MORE FROM THIS EXPERT